Abstract
While current treatments of multiple sclerosis (MS) effectively inhibit formation of focal lesions and relapses, most patients experience progression independent of relapse activity (PIRA). To understand PIRA, we analyzed nine prospectively acquired clinical and imaging outcomes in 176 relapsing-remitting and 215 progressive MS patients and 45 healthy volunteers, along with matched cellular and >5000 protein data in 1,042 cerebrospinal fluid (CSF) samples. Regressing out physiological aging and sex effects identified MS-related processes. Among these, compartmentalized inflammation and its effector mechanisms such as pyroptosis showed the strongest association with MS severity, irrespective of clinical categorization of patients. However, molecular processes affected localization of CNS injury: patients with predominant brain damage had proportionally higher neuroinflammation, while fibrosis and tissue hypoxia were linked to principal involvement of spinal cord. We did not identify inflammation-unrelated neurodegeneration; instead, CNS-related processes were beneficial, such as synaptogenesis. Machine learning-based CSF biomarker models predicted nine clinical and volumetric imaging outcomes in the independent cohort with accuracy exceeding published MS models.
These data show intra-individual diversity of putative disease mechanisms in MS and implicate processes related to compartmentalized neuroinflammation as leading candidate mechanisms of PIRA. Future drug development should include CNS-penetrant anti-inflammatory agents.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The research was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). This project was also supported in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. 75N910D00024, Task Order No. 75N91019F00130.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by National Institutes of Health Institutional Review Board. All subjects signed a written informed consent prior to inclusion in the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict-of-interest statement: The authors have declared that no conflict of interest exists.
Data Availability
The datasets generated during and/or analyzed during the current study as well as the custom codes used to perform analyses will be available from the corresponding author after the manuscript has been peer-reviewed and published.
Abbreviations
- 9HPT
- nine-hole peg test
- AI
- ambulation index
- ARMSS
- age-related multiple sclerosis severity
- BBB
- blood-brain barrier
- BD
- brain damage
- BPFr
- brain parenchymal fraction
- CCC
- concordance correlation coefficient
- CEL
- contrast-enhancing lesion
- CombiWISE
- combinatorial weight-adjusted disability score
- CNS
- central nervous system
- CSF
- cerebrospinal fluid
- DC
- dendritic cell
- EAE
- experimental autoimmune encephalomyelitis
- EBV
- Epstein-Barr virus
- EDSS
- expanded disability status scale
- EMT
- epithelial-mesenchymal transition
- EN
- elastic net
- FDR
- false discovery rate
- FLAIR
- fluid attenuation inversion recovery
- HV
- healthy volunteer
- IPA
- Ingenuity Pathway Analysis
- IPEC
- Instituto de Pesquisa Clinica Evandro Chagas
- IQR
- interquartile range
- lncRNA
- long non-coding RNA
- LP
- lumbar puncture
- MPRAGE
- magnetization-prepared rapid gradient echo
- MRI
- magnetic resonance imaging
- MS
- multiple sclerosis
- MS-DSS
- multiple sclerosis disease severity scale
- MSSS
- multiple sclerosis severity score
- NIH
- National Institutes of Health
- NK cell
- natural killer cell
- NO
- nitric oxide
- OOB
- out-of-bag
- PASAT
- paced auditory serial addition test
- PIRA
- progression independent of relapse activity
- PPMS
- primary progressive multiple sclerosis
- PMS
- progressive multiple sclerosis
- PRR
- patter-recognition receptors
- RF
- random forest
- RFU
- relative fluorescent units
- RMSE
- root mean square error
- ROS
- reactive oxygen species
- RRMS
- relapsing-remitting multiple sclerosis
- SC
- spinal cord
- SDMT
- symbol-digit modalities test
- SNRS
- Scripps neurological rating scale
- SPMS
- secondary progressive multiple sclerosis
- T25FW
- timed 25-foot walk
- T2LL
- T2 lesion load
